New HIV-1 integrase inhibitors developed

"Existing AIDS therapies are out of reach for most HIV-infected people in developing countries and, where available, they are limited by their toxicity and their cost. New anti-HIV agents are needed urgently to combat emerging viral resistance and reduce the side effects associated with currently available drugs," wrote scientists in Australia.

"Toward this end, LeapFrog, a de novo drug design program, was used to design novel, potent, and selective inhibitors of HIV-1 integrase. The designed compounds were synthesized and tested for in vitro inhibition of HIV-1 integrase," said M.T. Makhija and...

Want to see the full article?

• Purchase this article for only $3.00